Jefferies Financial Group Inc. Purchases New Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Jefferies Financial Group Inc. purchased a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 350,029 shares of the company's stock, valued at approximately $6,787,000. Jefferies Financial Group Inc. owned 1.00% of Oruka Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. FMR LLC grew its position in Oruka Therapeutics by 17.7% during the 4th quarter. FMR LLC now owns 5,512,300 shares of the company's stock worth $106,883,000 after purchasing an additional 830,000 shares during the period. Fairmount Funds Management LLC grew its position in Oruka Therapeutics by 5.0% during the 4th quarter. Fairmount Funds Management LLC now owns 3,371,922 shares of the company's stock worth $65,382,000 after purchasing an additional 160,000 shares during the period. VR Adviser LLC grew its position in Oruka Therapeutics by 6.5% during the 4th quarter. VR Adviser LLC now owns 3,285,620 shares of the company's stock worth $63,708,000 after purchasing an additional 200,000 shares during the period. RTW Investments LP grew its position in Oruka Therapeutics by 5.1% during the 4th quarter. RTW Investments LP now owns 1,945,649 shares of the company's stock worth $37,726,000 after purchasing an additional 95,001 shares during the period. Finally, Vanguard Group Inc. grew its position in Oruka Therapeutics by 4,161.2% during the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock worth $31,231,000 after purchasing an additional 1,572,853 shares during the period. 56.44% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Wall Street Zen raised Oruka Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. BTIG Research began coverage on shares of Oruka Therapeutics in a research note on Thursday, May 22nd. They set a "buy" rating on the stock. Wolfe Research began coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $20.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, February 7th. Finally, Wedbush reissued an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research note on Thursday, May 15th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $40.38.

Oruka Therapeutics Price Performance

Oruka Therapeutics stock traded down $0.81 during midday trading on Friday, reaching $11.04. The company had a trading volume of 327,851 shares, compared to its average volume of 225,192. The company has a market capitalization of $413.35 million, a P/E ratio of -1.76 and a beta of 0.25. Oruka Therapeutics, Inc. has a 12-month low of $5.49 and a 12-month high of $31.13. The firm's fifty day simple moving average is $9.73 and its 200-day simple moving average is $13.77.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. On average, analysts expect that Oruka Therapeutics, Inc. will post -3.41 EPS for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.